First AD

Second AD

Expert Perspectives: Navigating the Emerging Treatment Landscape of Combination Therapies in TN CLL—Applying Evidence to Clinical Practice

Video content above is prompted by the following:

For which patients would you consider a doublet vs triplet combination regimen? What factors would you consider among selecting the various triplet regimens (eg, acalabrutinib vs zanubrutinib vs pirtobrutinib plus venetoclax and obinutuzumab)?

Video Series

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

ASH 2024: Updates in the Treatment of CLL  

Peer Exchange

Panelists discuss how patient-specific factors including age, comorbidities, genetic profile, and treatment goals guide the selection between doublet and triplet regimens in chronic lymphocytic leukemia (CLL), with considerations like Bruton tyrosine kinase inhibitor tolerability, desire for time-limited therapy, and high-risk features informing the choice between various BTK inhibitor–based combinations with venetoclax and obinutuzumab.

Expert Insights in Selecting Frontline Therapies in TN CLL: Fixed-Duration Venetoclax vs Continuous BTKi

ASH 2024 Updates: SEQUOIA 5-Year Follow-Up and Expert Perspectives in Selecting Between Acalabrutinib vs Zanubrutinib in TN CLL

Real-World Observations: Firstline cBTKi Switches and Cardiac AEs in TN CLL

Clinical Insights: Exploring Combination Regimens in First-Line Treatment in CLL: SEQUOIA Arm D and BOVen Trials

Key Takeaways From the AMPLIFY Trial at ASH 2024: Fixed-Duration Acalabrutinib Plus Venetoclax With or Without Obinutuzumab vs Chemoimmunotherapy in TN CLL